Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma

Introduction Sodium glucose co‐transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co‐transporter 2 inhibitors have been shown to exert anticancer effects. However, the clinical value of these drugs as anticancer agents is yet to be evaluated. Case presentation...

Full description

Saved in:
Bibliographic Details
Published in:IJU case reports 2019-09, Vol.2 (5), p.269-271
Main Authors: Izumi, Keita, Iimura, Yasumasa, Hiruma, Kiyoshi, Touma, Tsuguhiro, Tsukamoto, Tetsuro
Format: Article
Language:English
Subjects:
Abdomen
Angiogenesis
Antidiabetics
Blood clots
Case Report
Case Reports
Cell cycle
Diabetes
diabetes mellitus
Edema
Enzymes
Glucose
Kidney cancer
Kinases
Liver
Metabolism
Metastasis
Mortality
Patients
renal cell carcinoma
sodium glucose transporter 2 inhibitor
Tumors
Veins & arteries
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Sodium glucose co‐transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co‐transporter 2 inhibitors have been shown to exert anticancer effects. However, the clinical value of these drugs as anticancer agents is yet to be evaluated. Case presentation A 72‐year‐old man presented to our hospital with frequent cough and dyspnea. Contrast‐enhanced computed tomography revealed renal cell carcinoma cT3bN0M1. Ipragliflozin, a sodium glucose co‐transporter 2 inhibitor, treatment was initiated to control blood glucose levels. Two years after diagnosis, computed tomography revealed remarkable tumor regression without any systemic therapy other than ipragliflozin. Conclusion Sodium glucose co‐transporter 2 inhibitors are potentially applicable as anticancer agents among patients with metastatic renal cell carcinoma.
ISSN:2577-171X
2577-171X
DOI:10.1002/iju5.12099